Literature DB >> 19660002

Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction.

Tae-Eun Kim1, Bo-Hyung Kim, Jung-Ryul Kim, Kyoung Soo Lim, Jang Hee Hong, Kyu-pyo Kim, Hwa-Sook Kim, Sang-Goo Shin, In-Jin Jang, Kyung-Sang Yu.   

Abstract

AIMS: Udenafil is a cyclic guanosine 3',5'-monophosphate-specific phosphodiesterase type 5 (PDE5) inhibitor developed for the treatment of erectile dysfunction. The aim was to evaluate the effect of food on the pharmacokinetics of udenafil.
METHODS: An open, randomized, three-way crossover study was conducted. Fifteen healthy male volunteers received a single 200-mg oral dose of udenafil while fasting, after a low-fat meal, and after a high-fat meal separated by 7-day washout periods. Serial blood samples were taken up to 48 h after oral administration.
RESULTS: Under fasting conditions, udenafil was rapidly absorbed and t(max) was observed typically 1.5 h after administration. The mean t(max) values after a low-fat meal and a high-fat meal were 2.6 and 2.1 h, respectively. The ratios (90% confidence intervals) of the geometric means compared with the fasting condition for C(max) and AUC(last) were 0.79 (0.70, 0.90) and 0.96 (0.89, 1.03) in the low fat-fed condition, respectively, and 1.01 (0.89, 1.15) and 1.03 (0.96, 1.11), respectively, in the high fat-fed condition.
CONCLUSIONS: The t(max) of udenafil was delayed under the fed conditions. However, although the C(max) was reduced by approximately 21% in the low fat-fed state, overall bioavailability was not affected when taken with food.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19660002      PMCID: PMC2732939          DOI: 10.1111/j.1365-2125.2009.03404.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  4 in total

1.  Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159.

Authors:  Hyounmie Doh; Chang Yell Shin; Miwon Son; Jun Il Ko; Moohi Yoo; Soon Hoe Kim; Won Bae Kim
Journal:  Arch Pharm Res       Date:  2002-12       Impact factor: 4.946

Review 2.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

3.  The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction.

Authors:  Jae-Seung Paick; Sae Woong Kim; Dae Yeol Yang; Ja Jong Kim; Sung Won Lee; Tai Young Ahn; Hyung Ki Choi; Jun-Kyu Suh; Sae Chul Kim
Journal:  J Sex Med       Date:  2008-01-21       Impact factor: 3.802

4.  Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects.

Authors:  Bo-Hyung Kim; Hyeong-Seok Lim; Jae-Yong Chung; Jung-Ryul Kim; Kyoung Soo Lim; Dong-Ryul Sohn; Joo-Youn Cho; Kyung-Sang Yu; Sang-Goo Shin; Jae-Seung Paick; In-Jin Jang
Journal:  Br J Clin Pharmacol       Date:  2008-03-03       Impact factor: 4.335

  4 in total
  6 in total

1.  Therapeutic effects of udenafil on pressure-overload cardiac hypertrophy.

Authors:  Hack-Lyoung Kim; Yong-Jin Kim; Kyung-Hee Kim; Seung-Pyo Lee; Hyung-Kwan Kim; Dae-Won Sohn; Byung-Hee Oh; Young-Bae Park
Journal:  Hypertens Res       Date:  2015-04-02       Impact factor: 3.872

2.  Modulation of inflammatory markers by miR-146a during replicative senescence in trabecular meshwork cells.

Authors:  Guorong Li; Coralia Luna; Jianming Qiu; David L Epstein; Pedro Gonzalez
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-06       Impact factor: 4.799

3.  Factors predicting outcomes of penile rehabilitation with udenafil 50 mg following radical prostatectomy.

Authors:  T-H Kim; Y-S Ha; S H Choi; E S Yoo; B W Kim; S-J Yun; W-J Kim; Y S Kwon; T G Kwon
Journal:  Int J Impot Res       Date:  2015-10-29       Impact factor: 2.896

4.  ULTIMATE-SHF trial (UdenafiL Therapy to Improve symptoMAtology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, double-blind trial.

Authors:  Kyung-Hee Kim; Hyung-Kwan Kim; In-Chang Hwang; Seung-Pyo Lee; Hyun-Jai Cho; Hyun-Jae Kang; Yong-Jin Kim; Dae-Won Sohn
Journal:  Trials       Date:  2013-06-22       Impact factor: 2.279

Review 5.  Udenafil for the treatment of erectile dysfunction.

Authors:  Min Chul Cho; Jae-Seung Paick
Journal:  Ther Clin Risk Manag       Date:  2014-05-14       Impact factor: 2.423

6.  Concentration-dependent differential effects of udenafil on viability, proliferation, and apoptosis in vascular endothelial and smooth muscle cells.

Authors:  Cheng-Hu Fang; Yi-Sun Song; Byung-Im So; Hyuck Kim; Jeong-Hun Shin; Kyung-Soo Kim
Journal:  Indian J Pharmacol       Date:  2014 May-Jun       Impact factor: 1.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.